This review highlights recent advances in managing liver disease in children, suggesting new non-invasive tests and examining risk factors.
Abstract Pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly common liver disease, with a global prevalence estimated up to 7.5% and substantial concern for hepatic and extrahepatic complications even in early life. In this paper, we review recent advances in epidemiology, genetics, early-life risk factors, natural history and comorbidities, focusing on emerging data published in the last 3 years. We also outline a practical approach to the management of MASLD in children, integrating newly developed non-invasive tests. Lastly, we provide key research questions to be studied in the coming years.
No takes yet. Share an insight, caveat, or question.
Lefere et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: